Wegovy (semaglutide) Injection 2.4 mg Cardiovascular Outcomes Data Presented at the American Heart Association Scientific Sessions and Simultaneously Published in the New England Journal of Medicine

PLAINSBORO, N.J., November 11, 2023– Novo Nordisk today announced the full results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly Wegovy® (semaglutide) injection 2.4 mg in adults...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials